Hospital General Universitario Gregorio Maranon
- Address
- lock Available on a paid plan
Hematologic Malignancies
Research at Hospital General Universitario Gregorio Maranon focuses on blood‑related cancers, aiming to improve survival and reduce treatment‑related toxicity.
- Acute myeloid leukemia
- Chronic myeloid leukemia
- Acute lymphoblastic leukemia
- Multiple myeloma
- Mantle cell lymphoma
- Diffuse large B‑cell lymphoma
- Myelodysplastic syndromes
- Chronic lymphocytic leukemia
Additional info: trials test novel targeted agents, cellular therapies and maintenance strategies to achieve deeper remissions.
Solid Tumor Oncology
Investigations target a broad range of solid tumors, evaluating new targeted drugs and combination regimens to extend progression‑free survival.
- Breast cancer
- Non‑small cell lung cancer
- Colorectal cancer
- Melanoma
- Gastric cancer
- Pancreatic ductal adenocarcinoma
- Renal cell carcinoma
- Hepatocellular carcinoma
- Sarcoma
Additional info: many studies incorporate biomarker‑driven enrollment such as KRAS, EGFR, HER2, and PD‑L1 status.
Immunology and Autoimmune Diseases
Trials address immune‑mediated conditions, testing innovative biologics and small molecules to control disease activity.
- Systemic lupus erythematosus
- Immune thrombocytopenia
- Atopic dermatitis
- Psoriasis
- Multiple sclerosis
- Rheumatoid arthritis
- Inflammatory bowel disease
- Chronic graft‑versus‑host disease
Additional info: objectives include improving quality of life and reducing flare frequency.
Cardiovascular and Metabolic Research
Research explores therapies for heart disease and metabolic disorders, seeking to lower event rates and improve organ function.
- Acute myocardial infarction
- Heart failure with reduced ejection fraction
- Atherosclerotic cardiovascular disease
- Type 2 diabetes
- Metabolic dysfunction‑associated steatohepatitis
- Hypertension
Additional info: studies often evaluate anti‑inflammatory or metabolic pathways such as IL‑6 inhibition.
Liver and Gastrointestinal Disorders
Clinical work includes chronic liver conditions and digestive‑tract cancers, aiming to halt disease progression and alleviate symptoms.
- Non‑alcoholic steatohepatitis
- Primary biliary cholangitis
- Cholestatic pruritus
- Hepatitis B
- Colorectal cancer
- Gastric adenocarcinoma
- Biliary tract cancer
Additional info: endpoints frequently involve liver fibrosis regression and patient‑reported itch scores.
Infectious Diseases and Transplant Complications
Studies address severe infections and post‑transplant complications, testing antivirals, antibiotics, and immune‑modulating protocols.
- COVID‑19
- Acute graft‑versus‑host disease
- Cytomegalovirus infection
- Clostridioides difficile infection
- Invasive fungal infections
- Transplant rejection
Additional info: safety and infection‑control outcomes are primary measures.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 37 therapeutic areas and 15 of 885 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 858 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 177 by active trials.
- 1Merck Sharp & Dohme LLC24active
lock +176 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC52trials
lock +111 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital General Universitario Gregorio Maranon
lock Showing 1 of 871 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | Bayer AG, Bayer Consumer Care AG | Phase II | Not Recruiting | Jun 2016 | Sep 2025 |
IMP list
lock Showing 1 of 885 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 78 | Unknown | 2016-11-17 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.